Skip to main content
Armata Pharmaceuticals, Inc. logo

Armata Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ARMP ISIN · US04216R1023 LEI · 549300QM1VCWH8KT0S21 US Manufacturing
Open in API
Filings indexed 1,011 across all filing types
Latest filing 2015-05-12 Capital/Financing Update
Country US United States of America
Listing US ARMP

About Armata Pharmaceuticals, Inc.

https://www.armatapharma.com/

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat the global threat of antibiotic-resistant infections. The company's core focus is on creating precisely targeted, high-purity phage-based treatments for serious bacterial infections. This approach aims to provide an effective alternative to conventional antibiotics by eliminating harmful bacteria while preserving the patient's healthy microbiome. Armata's pipeline includes product candidates targeting multi-drug resistant pathogens, supported by its in-house cGMP manufacturing facility for clinical and commercial supply.

Recent filings

Filing Released Lang Actions
S-1/A
Capital/Financing Update Classification · 100% confidence The document is an Amendment No. 1 to Form S-1 Registration Statement filed with the SEC, dated May 12, 2015. It is a registration statement under the Securities Act of 1933 for the registration of common stock shares by AmpliPhi Biosciences Corporation. The text includes details about the securities being registered, the offering, selling stockholders, and related legal and financial disclosures typical of an S-1 filing. This is a capital markets filing related to the company's initial or follow-on public offering registration, not a financial report, earnings release, or management discussion. It is not an announcement of a report but the actual registration statement document. Therefore, the appropriate classification is Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities such as registration statements for securities offerings.
2015-05-12 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on the appointment of a new CEO and board member, M. Scott Salka, including details about his offer letter, compensation, and background. There is no financial statement or comprehensive financial data presented, nor is this a full annual or quarterly report. The primary subject is a management change announcement. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is 6693 characters, which is sufficient to contain substantive information about the management change, not just a brief notice. Therefore, the appropriate classification is MANG with high confidence.
2015-05-01 English
10-K/A
Annual Report FY 2014
2015-04-30 English
Regulatory Filings 2015
Regulatory Filings
2015-04-30 English
SC 13G
Major Shareholding Notification
2015-04-27 English
Regulatory Filings 2015
Regulatory Filings
2015-04-24 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.